Following the failure of this trial, the double-blockade strategy was focused on a target downstream of MEK and AKT in a phase II trial testing selumetinib with MK-2206 (a selective pan-AKT inhibitor) or modified-FOLFOX (oxaliplatin, 85 mg/m2 intravenous, and fluorouracil, 2400 mg/m2 intravenous infusion over 46–48 h) in patients with metastatic, chemotherapy-refractory PC [59]. Here, AKT1 is linked to pachyonychia congenita.